Loading clinical trials...
Loading clinical trials...
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alnylam Pharmaceuticals
NCT04580420 · Primary Hyperoxaluria Type 1, End Stage Renal Disease
NCT00588562 · Primary Hyperoxaluria, Dent Disease, and more
NCT06065852 · Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, and more
NCT05843851 · Cystinosis, Primary Hyperoxaluria
NCT05993416 · Primary Hyperoxaluria Type 1 (PH1)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions